Rani Therapeutics (NASDAQ:RANI) (NASDAQ: RANI) is a clinical-stage biopharmaceutical company specializing in the development of oral delivery technologies for large-molecule drugs. Headquartered in San Jose, California, the company is pioneering a proprietary robotic pill platform designed to enable the non-invasive administration of biologics that traditionally require injection. By leveraging its innovative RaniPill™ capsule, Rani Therapeutics seeks to address patient compliance and improve the therapeutic reach of peptides, proteins and antibodies.
The company’s flagship technology integrates a swallowable capsule equipped with a micro-needle and controlled release mechanism. Upon reaching the small intestine, the capsule deploys its delivery system to inject the active molecule directly into the intestinal wall, facilitating systemic absorption. Rani Therapeutics is advancing several programs through preclinical and early clinical stages, with a focus on oral formulations of GLP-1 agonists for metabolic diseases and anti-TNF therapies for autoimmune disorders.
Founded in 2012 by serial entrepreneur Mir Imran, Rani Therapeutics emerged from InCube Labs with a vision to transform the administration of injectable medicines. Over the years, the company has built a cross-functional team of experts in drug formulation, medical device engineering and clinical development. Rani Therapeutics maintains research facilities in Silicon Valley and the East Coast, positioning itself to collaborate with academic institutions and pharmaceutical partners around the world.
Under the leadership of Mir Imran as chairman and CEO, Rani Therapeutics has raised multiple rounds of venture and public financing to support its pipeline advancement and manufacturing scale-up. With an eye toward global commercialization, the company is exploring strategic partnerships to bring its oral biologics platform to patients across North America, Europe and Asia. By offering an alternative to injectable regimens, Rani Therapeutics aims to redefine patient experience and broaden the impact of biologic therapies.
